N-(4-Trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide, 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-beuteamide, LEF-M; Teriflunomide; Leflunomide EP Impurity B; Aubagio; A1726; (2Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide; Femorix; HMR 1726; SU 20
雜質(zhì):
Leflunomide EP Impurity B
CAS號(hào):
163451-81-8
備用CAS:
108605-62-5 (Unspecified Stereochemistry)p
分子式:
C??H?F?N?O?
外觀:
白色固體
熔點(diǎn):
229-232°C
分子量:
270.21
儲(chǔ)存:
Hygroscopic, -20°C Freezer, Under Inert Atmosphere
溶解度:
DMSO, Methanol (Sparingly)
類(lèi)別:
Standards; Enzyme Activators and Inhibitors; Pharmaceutical/API Drug Impurities/Metabolites;
應(yīng)用:
A77 1726 (Leflunomide EP Impurity B) is the active metabolite of Leflunomide, a potent disease-modifying antirheumatic drug used in the treatment of rheumatoid arthritis. LEF-M interferes with dendritic cell function. The second Phase III study evaluating the efficacy of Genzyme’s teriflunomide therapy against relapsing forms of multiple sclerosis found the once-daily oral drug to be no less effective thanÂinjectable interferon beta 1a (Rebif®).
?您的位置：
